## Louise A Brinton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9026205/publications.pdf Version: 2024-02-01

	1536	2953
47,922	106	189
citations	h-index	g-index
	570	05000
572	572	35032
docs citations	times ranked	citing authors
	47,922 citations 572 docs citations	47,922 106 citations h-index 572 572 docs citations 572 times ranked

#	Article	IF	CITATIONS
1	Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually. Journal of the National Cancer Institute, 1989, 81, 1879-1886.	6.3	2,934
2	Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447, 1087-1093.	27.8	2,165
3	ESTIMATING THE POPULATION ATTRIBUTABLE RISK FOR MULTIPLE RISK FACTORS USING CASE-CONTROL DATA. American Journal of Epidemiology, 1985, 122, 904-914.	3.4	1,122
4	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
5	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
6	Type I and II Endometrial Cancers: Have They Different Risk Factors?. Journal of Clinical Oncology, 2013, 31, 2607-2618.	1.6	613
7	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
8	A common coding variant in CASP8 is associated with breast cancer risk. Nature Genetics, 2007, 39, 352-358.	21.4	591
9	Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genetics, 2012, 44, 651-658.	21.4	519
10	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
11	Cancer risk after a hospital discharge diagnosis of endometriosis. American Journal of Obstetrics and Gynecology, 1997, 176, 572-579.	1.3	496
12	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nature Genetics, 2009, 41, 579-584.	21.4	487
13	Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer, 1993, 71, 1258-1265.	4.1	477
14	Global trends in breast cancer incidence and mortality 1973–1997. International Journal of Epidemiology, 2005, 34, 405-412.	1.9	461
15	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	21.4	434
16	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
17	Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 439-443.	2.5	394
18	Performance of Common Genetic Variants in Breast-Cancer Risk Models. New England Journal of Medicine, 2010, 362, 986-993.	27.0	376

#	Article	IF	CITATIONS
19	Reproductive, menstrual, and medical risk factors for endometrial cancer: Results from a case-control study. American Journal of Obstetrics and Gynecology, 1992, 167, 1317-1325.	1.3	357
20	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
21	Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. Journal of Clinical Oncology, 2016, 34, 2888-2898.	1.6	349
22	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862.	10.7	335
23	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
24	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. PLoS Genetics, 2008, 4, e1000054.	3.5	315
25	Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1558-68.	2.5	299
26	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
27	The epidemiology of cervical carcinogenesis. Cancer, 1995, 76, 1888-1901.	4.1	281
28	A population-based case-control study of childhood leukemia in shanghai. Cancer, 1988, 62, 635-644.	4.1	276
29	Alcohol Consumption and Breast Cancer in the Epidemiologic Follow-up Study of the First National Health and Nutrition Examination Survey. New England Journal of Medicine, 1987, 316, 1169-1173.	27.0	261
30	Factors influencing the age at natural menopause. Journal of Chronic Diseases, 1987, 40, 995-1002.	1.2	260
31	Is Male Breast Cancer Similar or Different than Female Breast Cancer?. Breast Cancer Research and Treatment, 2004, 83, 77-86.	2.5	259
32	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	21.4	256
33	Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai breast cancer study. International Journal of Cancer, 2000, 87, 295-300.	5.1	240
34	Mammographic densities and risk of breast cancer. Cancer, 1991, 67, 2833-2838.	4.1	232
35	Human Papillomavirus Infection and Cervical Cancer in Latin America. New England Journal of Medicine, 1989, 320, 1437-1441.	27.0	229
36	Recent Trends in Breast Cancer Among Younger Women in the United States. Journal of the National Cancer Institute, 2008, 100, 1643-1648.	6.3	226

#	Article	IF	CITATIONS
37	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
38	Menstrual Factors and Risk of Breast Cancer. Cancer Investigation, 1988, 6, 245-254.	1.3	203
39	Recent trends in breast cancer incidence and mortality. Environmental and Molecular Mutagenesis, 2002, 39, 82-88.	2.2	203
40	Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1157-1166.	2.5	203
41	Ovarian cancer risk associated with varying causes of infertility. Fertility and Sterility, 2004, 82, 405-414.	1.0	200
42	Circulating Carotenoids and Risk of Breast Cancer: Pooled Analysis of Eight Prospective Studies. Journal of the National Cancer Institute, 2012, 104, 1905-1916.	6.3	200
43	In situ and invasive vulvar cancer incidence trends (1973 to 1987). American Journal of Obstetrics and Gynecology, 1992, 166, 1482-1485.	1.3	193
44	Association of HLA Class I and II Alleles and Extended Haplotypes With Nasopharyngeal Carcinoma in Taiwan. Journal of the National Cancer Institute, 2002, 94, 1780-1789.	6.3	193
45	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	6.3	186
46	Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. Gynecologic Oncology, 2013, 129, 277-284.	1.4	185
47	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
48	Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer, 2004, 100, 1595-1604.	4.1	183
49	Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 1997, 1, 362-375.	1.1	183
50	Epidemiology of uterine cervical cancer. Journal of Chronic Diseases, 1986, 39, 1051-1065.	1.2	182
51	CYP2E1 Genetic Polymorphisms and Risk of Nasopharyngeal Carcinoma in Taiwan. Journal of the National Cancer Institute, 1997, 89, 1207-1212.	6.3	178
52	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
53	A CASE-CONTROL STUDY OF CANCERS OF THE NASAL CAVITY AND PARANASAL SINUSES. American Journal of Epidemiology, 1984, 119, 896-906.	3.4	170
54	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	3.1	169

#	Article	IF	CITATIONS
55	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	2.9	168
56	Combined Microsatellite Instability, <i>MLH1</i> Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 4301-4308.	1.6	163
57	Heterogeneous Etiology of Squamous Carcinoma of the Vulva. Obstetrics and Gynecology, 1996, 87, 59-64.	2.4	157
58	Tumor Variants by Hormone Receptor Expression in White Patients With Node-Negative Breast Cancer From the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology, 2001, 19, 18-27.	1.6	157
59	PARITY AS A RISK FACTOR FOR CERVICAL CANCER. American Journal of Epidemiology, 1989, 130, 486-496.	3.4	152
60	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	2.9	152
61	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	6.3	152
62	EVIDENCE OF A HEALTHY ESTROGEN USER SURVIVOR EFFECT. Epidemiology, 1995, 6, 227-231.	2.7	151
63	Breast cancer in Sub-Saharan Africa: opportunities for prevention. Breast Cancer Research and Treatment, 2014, 144, 467-478.	2.5	149
64	RISK FACTORS FOR BENIGN BREAST DISEASE. American Journal of Epidemiology, 1981, 113, 203-214.	3.4	147
65	Long-term use of oral contraceptives and risk of invasive cervical cancer. International Journal of Cancer, 1986, 38, 339-344.	5.1	146
66	Height and weight at various ages and risk of breast cancer. Annals of Epidemiology, 1992, 2, 597-609.	1.9	146
67	Using deep convolutional neural networks to identify and classify tumor-associated stroma in diagnostic breast biopsies. Modern Pathology, 2018, 31, 1502-1512.	5.5	145
68	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Human Genetics, 2006, 119, 376-388.	3.8	144
69	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
70	Evidence for a Common Etiology for Endometrial Carcinomas and Malignant Mixed Mullerian Tumors. Gynecologic Oncology, 1998, 69, 253-257.	1.4	142
71	CANCER RISK AFTER EVALUATION FOR INFERTILITY. American Journal of Epidemiology, 1989, 129, 712-722.	3.4	141
72	Relationship of Benign Gynecologic Diseases to Subsequent Risk of Ovarian and Uterine Tumors. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2929-2935.	2.5	140

#	Article	IF	CITATIONS
73	Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United) Tj ETQq $1$	1 0.784314 1.8	rgBT /Overlo
74	Herpes simplex virus type 2: A possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. International Journal of Cancer, 1991, 49, 335-340.	5.1	135
75	Menopausal estrogen use and risk of breast cancer. Cancer, 1981, 47, 2517-2522.	4.1	134
76	Effect of twinship on incidence of cancer of the testis, breast, and other sites (Sweden). Cancer Causes and Control, 1995, 6, 519-524.	1.8	133
77	Relationship Between Mammographic Density and Breast Cancer Death in the Breast Cancer Surveillance Consortium. Journal of the National Cancer Institute, 2012, 104, 1218-1227.	6.3	133
78	Genetic Polymorphisms in Base-Excision Repair Pathway Genes and Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 353-358.	2.5	132
79	Body mass index and risk of ovarian cancer. Cancer, 2009, 115, 812-822.	4.1	132
80	Sexual behavior, venereal diseases, hygiene practices, and invasive cervical cancer in a high-risk population. Cancer, 1990, 65, 380-386.	4.1	131
81	Prenatal and Perinatal Risk Factors for Breast Cancer in Young Women. Epidemiology, 1997, 8, 181-187.	2.7	131
82	Ovarian Cancer Risk After the Use of Ovulation-Stimulating Drugs. Obstetrics and Gynecology, 2004, 103, 1194-1203.	2.4	131
83	Physical activity, sedentary behavior, and endometrial cancer risk in the NIHâ€AARP Diet and Health Study. International Journal of Cancer, 2009, 124, 2139-2147.	5.1	131
84	Anthropometric and Hormonal Risk Factors for Male Breast Cancer: Male Breast Cancer Pooling Project Results. Journal of the National Cancer Institute, 2014, 106, djt465-djt465.	6.3	131
85	Prospective Evaluation of Risk Factors for Male Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 1477-1481.	6.3	130
86	An international comparison of male and female breast cancer incidence rates. International Journal of Cancer, 2013, 132, 1918-1926.	5.1	127
87	Mortality among Augmentation Mammoplasty Patients. Epidemiology, 2001, 12, 321-326.	2.7	126
88	Recent trends in cervix uteri cancer. Cancer, 1989, 64, 2184-2190.	4.1	124
89	Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes and Control, 1998, 9, 199-207.	1.8	123
90	Intake of food groups and associated micronutrients in relation to risk of early-stage breast cancer. , 1999, 82, 315-321.		123

#	Article	IF	CITATIONS
91	A Population-based Case-Control Study of Dietary Factors and Endometrial Cancer in Shanghai, People's Republic of China. American Journal of Epidemiology, 1993, 137, 155-165.	3.4	122
92	Causes of Infertility as Predictors of Subsequent Cancer Risk. Epidemiology, 2005, 16, 500-507.	2.7	122
93	Wood dust and sino-nasal cancer: Pooled reanalysis of twelve case-control studies. American Journal of Industrial Medicine, 1995, 28, 151-166.	2.1	121
94	Cigarette Smoking and Invasive Cervical Cancer. JAMA - Journal of the American Medical Association, 1986, 255, 3265.	7.4	120
95	Sinonasal cancer and occupational exposures: a pooled analysis of 12 case-control studies. Cancer Causes and Control, 2002, 13, 147-157.	1.8	120
96	Breast cancers among very young premenopausal women (United States). Cancer Causes and Control, 2003, 14, 151-160.	1.8	120
97	Intrauterine environments and breast cancer risk: meta-analysis and systematic review. Breast Cancer Research, 2008, 10, R8.	5.0	118
98	Cigarette smoking, alcohol consumption and risk of nasopharyngeal carcinoma in Taiwan. Cancer Causes and Control, 1999, 10, 201-207.	1.8	116
99	Dietary exposure to nitrite and nitrosamines and risk of nasopharyngeal carcinoma in Taiwan. , 2000, 86, 603-609.		116
100	General and Abdominal Obesity and Survival among Young Women with Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1871-1877.	2.5	115
101	Occupational Exposures and Female Breast Cancer Mortality in the United States. Journal of Occupational and Environmental Medicine, 1995, 37, 336-348.	1.7	114
102	Breast cancer following augmentation mammoplasty (United States). Cancer Causes and Control, 2000, 11, 819-827.	1.8	113
103	Breast cancer risk associated with gynecologic surgery and indications for such surgery. , 1997, 70, 150-154.		112
104	Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer, 2003, 98, 814-821.	4.1	112
105	Dietary fiber intake and risk of breast cancer in postmenopausal women: the National Institutes of Health–AARP Diet and Health Study. American Journal of Clinical Nutrition, 2009, 90, 644-651.	4.7	112
106	The ma le factor in the etiology of cervical cancer among sexually monogamous women. International Journal of Cancer, 1989, 44, 199-203.	5.1	111
107	Use of Hormone Replacement Therapy and Adenocarcinomas and Squamous Cell Carcinomas of the Uterine Cervix. Gynecologic Oncology, 2000, 77, 149-154.	1.4	111
108	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111

#	Article	IF	CITATIONS
109	Metabolic Syndrome and Risk of Endometrial Cancer in the United States: A Study in the SEER–Medicare Linked Database. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 261-267.	2.5	109
110	ESTROGEN RECEPTORS AND BREAST CANCER. Epidemiologic Reviews, 1986, 8, 42-59.	3.5	107
111	Oral Contraceptive Use and Risk of Invasive Cervical Cancer. International Journal of Epidemiology, 1990, 19, 4-11.	1.9	107
112	Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: A population-based case–control study and meta-analyses. International Journal of Cancer, 2007, 120, 2696-2703.	5.1	107
113	p53 polymorphism and risk of cervical cancer. Nature, 1998, 396, 531-532.	27.8	105
114	Case-control study of in situ and invasive carcinoma of the vagina. Gynecologic Oncology, 1990, 38, 49-54.	1.4	104
115	Factors Associated with Advanced Disease Stage at Diagnosis in a Population-based Study of Patients with Newly Diagnosed Breast Cancer. American Journal of Epidemiology, 2007, 166, 1035-1044.	3.4	104
116	Menopausal Hormone Therapy and Ovarian Cancer Risk in the National Institutes of Health–AARP Diet and Health Study Cohort. Journal of the National Cancer Institute, 2006, 98, 1397-1405.	6.3	103
117	DIET AND THE RISK OF INVASIVE CERVICAL CANCER AMONG WHITE WOMEN IN THE UNITED STATES. American Journal of Epidemiology, 1990, 132, 432-445.	3.4	102
118	Body Mass Index and Risk of Lung Cancer Among Never, Former, and Current Smokers. Journal of the National Cancer Institute, 2012, 104, 778-789.	6.3	102
119	Risk Factors for Epithelial Ovarian Cancer in Beijing, China. International Journal of Epidemiology, 1992, 21, 23-29.	1.9	101
120	Estrogen Replacement Therapy and Breast Cancer Risk. Epidemiologic Reviews, 1993, 15, 66-79.	3.5	101
121	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	6.2	101
122	Alcohol consumption and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies. International Journal of Epidemiology, 2016, 45, 916-928.	1.9	101
123	MAMMOGRAPHIC PARENCHYMAL PATTERNS AS INDICATORS OF BREAST CANCER RISK. American Journal of Epidemiology, 1989, 129, 518-526.	3.4	100
124	A Case-Control Study of Nutrient Status and Invasive Cervical Cancer. American Journal of Epidemiology, 1991, 134, 1335-1346.	3.4	100
125	Risk of Estrogen Receptor–Positive and –Negative Breast Cancer and Single–Nucleotide Polymorphism 2q35-rs13387042. Journal of the National Cancer Institute, 2009, 101, 1012-1018.	6.3	99
126	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99

#	Article	IF	CITATIONS
127	Association of body size and fat distribution with risk of breast cancer among Chinese women. International Journal of Cancer, 2001, 94, 449-455.	5.1	98
128	Ovulation induction and cancer risk. Fertility and Sterility, 2005, 83, 261-274.	1.0	98
129	Lifetime Weight History and Endometrial Cancer Risk by Type of Menopausal Hormone Use in the NIH-AARP Diet and Health Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 723-730.	2.5	98
130	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
131	BODY SIZE AND BREAST CANCER RISK ASSESSED IN WOMEN PARTICIPATING IN THE BREAST CANCER DETECTION DEMONSTRATION PROJECT. American Journal of Epidemiology, 1989, 130, 1133-1141.	3.4	97
132	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
133	Recreational Physical Activity and Breast Cancer Risk among Women under Age 45 Years. American Journal of Epidemiology, 1998, 147, 273-280.	3.4	94
134	Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes and Control, 2001, 12, 103-110.	1.8	94
135	Uterine Cancer after Use of Clomiphene Citrate to Induce Ovulation. American Journal of Epidemiology, 2005, 161, 607-615.	3.4	94
136	Prediagnosis Body Mass Index, Physical Activity, and Mortality in Endometrial Cancer Patients. Journal of the National Cancer Institute, 2013, 105, 342-349.	6.3	94
137	EPIDEMIOLOGY OF HYDATIDIFORM MOLE AND CHORIOCARCINOMA. Epidemiologic Reviews, 1984, 6, 52-75.	3.5	93
138	Ovarian cancer risk factors by histologic subtypes in the NIHâ€AARP diet and health study. International Journal of Cancer, 2012, 131, 938-948.	5.1	93
139	Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Research, 2013, 15, R34.	5.0	92
140	Oral contraceptives and cervical neoplasia. Contraception, 1991, 43, 581-595.	1.5	91
141	Association of Estrogen Metabolism with Breast Cancer Risk in Different Cohorts of Postmenopausal Women. Cancer Research, 2017, 77, 918-925.	0.9	91
142	Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Research and Treatment, 2010, 119, 185-192.	2.5	90
143	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
144	Alcohol and Risk of Breast Cancer by Histologic Type and Hormone Receptor Status in Postmenopausal Women: The NIH-AARP Diet and Health Study. American Journal of Epidemiology, 2009, 170, 308-317.	3.4	89

#	Article	IF	CITATIONS
145	Diet During Adolescence and Risk of Breast Cancer Among Young Women. Journal of the National Cancer Institute, 1998, 90, 226-233.	6.3	88
146	Breast cancer risk associated with ovulation-stimulating drugs. Human Reproduction, 2004, 19, 2005-2013.	0.9	88
147	Recreational physical activity and survival among young women with breast cancer. Cancer, 2006, 107, 1777-1785.	4.1	88
148	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. International Journal of Epidemiology, 2018, 47, 526-536.	1.9	88
149	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nature Communications, 2016, 7, 11843.	12.8	86
150	Epidemiology of Genital Papillomaviruses and Cervical Cancer. Clinical Infectious Diseases, 1989, 11, 426-439.	5.8	85
151	Nutrition and cervical neoplasia. Cancer Causes and Control, 1996, 7, 113-126.	1.8	84
152	Association of ESR1 gene tagging SNPs with breast cancer risk. Human Molecular Genetics, 2009, 18, 1131-1139.	2.9	84
153	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies. Cancer Causes and Control, 2013, 24, 989-1004.	1.8	84
154	Endometrial Cancer Risk Factors by 2 Main Histologic Subtypes. American Journal of Epidemiology, 2013, 177, 142-151.	3.4	84
155	Risk factors for penile cancer: Results from a caseâ€control study in china. International Journal of Cancer, 1991, 47, 504-509.	5.1	83
156	Breast Cancer following Breast Reduction Surgery in Sweden. Plastic and Reconstructive Surgery, 2000, 106, 755-762.	1.4	83
157	Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecologic Oncology, 2014, 135, 297-304.	1.4	83
158	A Case-Control Study of Nutrient Status and Invasive Cervical Cancer. American Journal of Epidemiology, 1991, 134, 1347-1355.	3.4	82
159	Alcohol Consumption and Breast Cancer Risk among Women under Age 45 Years. Epidemiology, 1997, 8, 231.	2.7	82
160	Pregnancy Characteristics and Maternal Risk of Breast Cancer. Epidemiology, 1998, 9, 641-647.	2.7	82
161	Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health–AARP Diet and Health Study. Breast Cancer Research, 2008, 10, R38.	5.0	82
162	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research, 2010, 12, R110.	5.0	82

#	Article	IF	CITATIONS
163	Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatrica, International Journal of Paediatrics, 2011, 100, 814-818.	1.5	81
164	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
165	Endometrial Carcinoma Risks among Menopausal Estrogen plus Progestin and Unopposed Estrogen Users in a Cohort of Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1724-1731.	2.5	80
166	C-Reactive Protein Concentrations and Subsequent Ovarian Cancer Risk. Obstetrics and Gynecology, 2007, 109, 933-941.	2.4	80
167	Screening for Cervical Cancer in Latin America: A Case-Control Study. International Journal of Epidemiology, 1992, 21, 1050-1056.	1.9	79
168	Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: Results from a seroepidemiological case-control study. Obstetrics and Gynecology, 1997, 90, 748-754.	2.4	79
169	Recent changes in endometrial cancer trends among menopausal-age US women. Cancer Epidemiology, 2013, 37, 374-377.	1.9	79
170	A CASE-CONTROL STUDY OF BREAST CANCER STRATIFIED BY ESTROGEN RECEPTOR STATUS. American Journal of Epidemiology, 1987, 125, 184-194.	3.4	78
171	Breast Enlargement and Reduction: Results from a Breast Cancer Case-Control Study. Plastic and Reconstructive Surgery, 1996, 97, 269-275.	1.4	78
172	Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Research, 2007, 67, 3027-3035.	0.9	78
173	Adenocarcinomas of the Uterine Cervix: The Epidemiology of an Increasing Problem. Epidemiologic Reviews, 1993, 15, 486-491.	3.5	77
174	Ethnicity and variation in breast cancer incidence. , 1997, 73, 349-355.		77
175	Supravaginal uterine amputation in Denmark 1978–1988 and risk of cancer. Gynecologic Oncology, 1992, 45, 198-201.	1.4	76
176	Cancer Risk at Sites Other than the Breast Following Augmentation Mammoplasty. Annals of Epidemiology, 2001, 11, 248-256.	1.9	76
177	Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal of Epidemiology, 2012, 176, 269-278.	3.4	76
178	Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1081-1089.	2.5	76
179	Characteristics of a Population of Women with Breast Implants Compared with Women Seeking Other Types of Plastic Surgery. Plastic and Reconstructive Surgery, 2000, 105, 919-927.	1.4	75
180	Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden. Cancer, 2001, 91, 478-483.	4.1	75

#	Article	IF	CITATIONS
181	Epidemiologic issues related to the association between physical activity and breast cancer. Cancer, 1998, 83, 600-610.	4.1	73
182	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	5.1	73
183	InÂvitro fertilization and risk of breastÂand gynecologic cancers: a retrospective cohort study withinÂthe Israeli Maccabi Healthcare Services. Fertility and Sterility, 2013, 99, 1189-1196.	1.0	73
184	Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. American Journal of Obstetrics and Gynecology, 2003, 188, 657-663.	1.3	72
185	Mortality Rates Among Augmentation Mammoplasty Patients. Epidemiology, 2006, 17, 162-169.	2.7	72
186	Prospective study of physical activity and risk of postmenopausal breast cancer. Breast Cancer Research, 2008, 10, R92.	5.0	72
187	Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3150-3160.	2.5	72
188	A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes and Control, 1997, 8, 130-138.	1.8	71
189	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	2.9	71
190	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
191	Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. JAMA Oncology, 2018, 4, 516.	7.1	71
192	Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers. International Journal of Cancer, 1990, 45, 860-864.	5.1	70
193	CIGARETTE SMOKING AND BREAST CANCER1. American Journal of Epidemiology, 1986, 123, 614-622.	3.4	69
194	CHORIOCARCINOMA INCIDENCE IN THE UNITED STATES. American Journal of Epidemiology, 1986, 123, 1094-1100.	3.4	69
195	Breastfeeding and breast cancer risk. Cancer Causes and Control, 1995, 6, 199-208.	1.8	69
196	Oral Contraceptives and Breast Cancer. International Journal of Epidemiology, 1982, 11, 316-322.	1.9	68
197	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
198	Case-control study of human papillomaviruses and cervical cancer in Latin America. International Journal of Cancer, 1987, 40, 450-454.	5.1	67

#	Article	IF	CITATIONS
199	Cigarette Smoking and the Risk of Endometrial Cancer. American Journal of Epidemiology, 1993, 137, 281-291.	3.4	67
200	Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes and Control, 2001, 12, 153-161.	1.8	67
201	Risk of Breast Cancer Classified by Joint Estrogen Receptor and Progesterone Receptor Status among Women 20-44 Years of Age. American Journal of Epidemiology, 2002, 156, 507-516.	3.4	67
202	Terminal Duct Lobular Unit Involution of the Normal Breast: Implications for Breast Cancer Etiology. Journal of the National Cancer Institute, 2014, 106, .	6.3	67
203	Menopausal hormone therapy and risk of endometrial cancer. Journal of Steroid Biochemistry and Molecular Biology, 2014, 142, 83-89.	2.5	67
204	Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype. Cancer Research, 2018, 78, 6011-6021.	0.9	67
205	Sexual and Reproductive Risk Factors for Invasive Squamous Cell Cervical Cancer. Journal of the National Cancer Institute, 1987, , .	6.3	65
206	A population-based case-control study of endometrial cancer in shanghai, china. International Journal of Cancer, 1991, 49, 38-43.	5.1	65
207	Diet and the risk of in situ cervical cancer among white women in the United States. Cancer Causes and Control, 1991, 2, 17-29.	1.8	65
208	Risk Factors for Cervical Cancer by Histology. Gynecologic Oncology, 1993, 51, 301-306.	1.4	65
209	Circulating Adipokine Levels and Endometrial Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1304-1312.	2.5	65
210	Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. Journal of Clinical Oncology, 2015, 33, 2041-2050.	1.6	65
211	The Relationship of Silicone Breast Implants and Cancer at Other Sites. Plastic and Reconstructive Surgery, 2007, 120, 94S-102S.	1.4	64
212	Reproductive and Hormonal Factors and Lung Cancer Risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 900-911.	2.5	64
213	Single Nucleotide Polymorphisms in the <i>TP53</i> Region and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Research, 2009, 69, 2349-2357.	0.9	63
214	Long-term overall and disease-specific mortality associated with benign gynecologic surgery performed at different ages. Menopause, 2014, 21, 592-601.	2.0	63
215	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
216	Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF–LTA) and breast cancer risk. Human Genetics, 2007, 121, 483-490.	3.8	62

#	Article	IF	CITATIONS
217	Discovery and validation of methylation markers for endometrial cancer. International Journal of Cancer, 2014, 135, 1860-1868.	5.1	62
218	Invasive Cervical Cancer and Smoking in Latin America. Journal of the National Cancer Institute, 1989, 81, 205-211.	6.3	61
219	Heterogeneity of the Effect of Family History on Breast Cancer Risk. Epidemiology, 1991, 2, 276-284.	2.7	61
220	Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65 000 sterilized women. International Journal of Epidemiology, 2004, 33, 596-602.	1.9	61
221	Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology, 2005, 193, 668-674.	1.3	61
222	Long-term effects of ovulation-stimulating drugs on cancer risk. Reproductive BioMedicine Online, 2007, 15, 38-44.	2.4	61
223	DNA Hypermethylation of <i>ESR1</i> and <i>PGR</i> in Breast Cancer: Pathologic and Epidemiologic Associations. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3036-3043.	2.5	60
224	Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer, 2002, 95, 1611-1617.	4.1	59
225	Risk Factors for Mortality in Middle-aged Women. Archives of Internal Medicine, 2006, 166, 2469.	3.8	59
226	Risk for breast cancer among women with endometriosis. International Journal of Cancer, 2007, 120, 1372-1375.	5.1	59
227	Leukocyte telomere length in a population-based case–control study of ovarian cancer: a pilot study. Cancer Causes and Control, 2010, 21, 77-82.	1.8	59
228	Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?. International Journal of Cancer, 2013, 132, 417-426.	5.1	59
229	Characteristics of respondents and non-respondents from a case-control study of breast cancer in younger women. International Journal of Epidemiology, 2000, 29, 793-798.	1.9	58
230	Menopause, hormone replacement therapy and cancer. Maturitas, 2001, 39, 97-115.	2.4	58
231	Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Research, 2010, 12, R98.	5.0	58
232	Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients. Breast Cancer Research, 2017, 19, 8.	5.0	58
233	The Obesity-Associated Polymorphisms FTO rs9939609 and MC4R rs17782313 and Endometrial Cancer Risk in Non-Hispanic White Women. PLoS ONE, 2011, 6, e16756.	2.5	58
234	Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1610-1616.	2.5	57

#	Article	IF	CITATIONS
235	Estrogen metabolism and breast cancer risk among postmenopausal women: a case–cohort study within B~FIT. Carcinogenesis, 2014, 35, 346-355.	2.8	57
236	Stage of breast cancer in relation to body mass index and bra cup size. , 1999, 82, 23-27.		56
237	Childhood tumor risk after treatment with ovulation-stimulating drugs. Fertility and Sterility, 2004, 81, 1083-1091.	1.0	56
238	TheATMmissense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer. Human Mutation, 2006, 27, 538-544.	2.5	56
239	Adulthood Lifetime Physical Activity and Breast Cancer. Epidemiology, 2008, 19, 226-236.	2.7	56
240	Pooled analysis of active cigarette smoking and invasive breast cancer risk in 14 cohort studies. International Journal of Epidemiology, 2017, 46, dyw288.	1.9	56
241	Antibodies Against <i>Chlamydia trachomatis</i> and Ovarian Cancer Risk in Two Independent Populations. Journal of the National Cancer Institute, 2019, 111, 129-136.	6.3	56
242	Breast Cancer following Breast Reduction Surgery in Sweden. Plastic and Reconstructive Surgery, 2000, 106, 755-762.	1.4	54
243	Serum antimüllerian hormone in healthy premenopausal women. Fertility and Sterility, 2011, 95, 2718-2721.	1.0	54
244	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	2.5	54
245	Intrauterine devices and endometrial cancer risk: A pooled analysis of the <scp>E</scp> pidemiology of <scp>E</scp> ndometrial <scp>C</scp> ancer <scp>C</scp> onsortium. International Journal of Cancer, 2015, 136, E410-22.	5.1	54
246	Breastfeeding and Endometrial Cancer Risk. Obstetrics and Gynecology, 2017, 129, 1059-1067.	2.4	52
247	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
248	Expression of TGF-Î <sup>2</sup> signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Research and Treatment, 2010, 121, 727-735.	2.5	51
249	Fineâ€scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	5.1	51
250	Risk of Cancer in Children Conceived by Assisted Reproductive Technology. Pediatrics, 2016, 137, e20152061.	2.1	51
251	Cancer Progress and Priorities: Uterine Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 985-994.	2.5	51
252	Case control study of cervical cancer in Herrera Province, Republic of Panama. International Journal of Cancer, 1985, 36, 55-60.	5.1	50

#	Article	IF	CITATIONS
253	Physical Activity and Risk of Endometrial Cancer. Epidemiology, 1993, 4, 342-349.	2.7	50
254	Electric Blanket Use and Breast Cancer Risk among Younger Women. American Journal of Epidemiology, 1998, 148, 556-563.	3.4	50
255	Hormonal Markers in Breast Cancer: Coexpression, Relationship with Pathologic Characteristics, and Risk Factor Associations in a Population-Based Study. Cancer Research, 2007, 67, 10608-10617.	0.9	50
256	Association between reproductive factors and breast cancer survival in younger women. Breast Cancer Research and Treatment, 2007, 103, 93-102.	2.5	50
257	Prognostic Significance of Mammographic Density Change After Initiation of Tamoxifen for ER-Positive Breast Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	50
258	Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. Clinical Cancer Research, 2019, 25, 5937-5946.	7.0	50
259	Endometrial cancer chemoprevention: Implications of diverse pathways of carcinogenesis. Journal of Cellular Biochemistry, 1995, 59, 160-164.	2.6	49
260	Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women. Cancer Causes and Control, 2001, 12, 317-324.	1.8	49
261	Common genetic variation in <i>TP53</i> and its flanking genes, <i>WDR79</i> and <i>ATP1B2</i> , and susceptibility to breast cancer. International Journal of Cancer, 2007, 121, 2532-2538.	5.1	49
262	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
263	Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa. Breast Cancer Research and Treatment, 2017, 162, 105-114.	2.5	49
264	Laterality of breast cancer in the United States. Cancer Causes and Control, 1996, 7, 539-543.	1.8	48
265	Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes and Control, 2007, 18, 439-447.	1.8	48
266	Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case–control study within the Bâ^¼FIT cohort. Endocrine-Related Cancer, 2013, 20, 151-160.	3.1	48
267	Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . Cancer Research, 2014, 74, 852-861.	0.9	48
268	Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case–control study. Breast Cancer Research and Treatment, 2016, 159, 163-172.	2.5	48
269	Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. International Journal of Cancer, 2017, 140, 600-610.	5.1	48
270	Epidemiology of Minimal Breast Cancer. JAMA - Journal of the American Medical Association, 1983, 249, 483.	7.4	47

#	Article	IF	CITATIONS
271	Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 648-656.	2.5	47
272	Oral contraceptives and endometrial cancer: Do other risk factors modify the association?. International Journal of Cancer, 1993, 54, 243-248.	5.1	46
273	Serum levels of sex hormones and breast cancer risk in premenopausal women: a case–control study (USA). Cancer Causes and Control, 2004, 15, 45-53.	1.8	46
274	Analysis of Serum Metabolic Profiles in Women with Endometrial Cancer and Controls in a Population-Based Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3216-3223.	3.6	46
275	Coffee intake and breast cancer risk in the NIHâ€AARP diet and health study cohort. International Journal of Cancer, 2012, 131, 452-460.	5.1	46
276	Reproductive Factors, Oral Contraceptive Use, and Risk of Colorectal Cancer. Epidemiology, 1997, 8, 75-79.	2.7	45
277	Serum concentrations of organochlorine compounds and endometrial cancer risk (United States). Cancer Causes and Control, 1998, 9, 417-424.	1.8	45
278	Increased risk of early-stage breast cancer related to consumption of sweet foods among women less than age 45 in the United States. Cancer Causes and Control, 2002, 13, 937-946.	1.8	45
279	Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers. Cancer Causes and Control, 2007, 18, 1187-1198.	1.8	45
280	Fertility Drugs and Ovarian Cancer. Epidemiologic Reviews, 1998, 20, 237-257.	3.5	44
281	Comparison of the 60- and 100-Item NCI-Block Questionnaires With Validation Data. Nutrition and Cancer, 1999, 34, 70-75.	2.0	44
282	Risk of Connective Tissue Disorders among Breast Implant Patients. American Journal of Epidemiology, 2004, 160, 619-627.	3.4	44
283	Variation in breast cancer hormone receptor andHER2levels by etiologic factors: A population-based analysis. International Journal of Cancer, 2007, 121, 1079-1085.	5.1	44
284	Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women?. Cancer Epidemiology, 2010, 34, 580-586.	1.9	44
285	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
286	Tobacco smoking,NAT2 acetylation genotype and breast cancer risk. International Journal of Cancer, 2006, 119, 1961-1969.	5.1	43
287	Reproductive risk factors for endometrial cancer among Polish women. British Journal of Cancer, 2007, 96, 1450-1456.	6.4	43
288	Telomere structure and maintenance gene variants and risk of five cancer types. International Journal of Cancer, 2016, 139, 2655-2670.	5.1	43

#	Article	IF	CITATIONS
289	Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women. Fertility and Sterility, 2017, 107, 1012-1022.e2.	1.0	43
290	Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. Journal of the National Cancer Institute, 2019, 111, 137-145.	6.3	43
291	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
292	Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women. Breast Cancer Research and Treatment, 2006, 98, 157-165.	2.5	42
293	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Human Molecular Genetics, 2009, 18, 2297-2304.	2.9	42
294	Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis, 2010, 31, 827-833.	2.8	42
295	Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. Fertility and Sterility, 2013, 100, 1660-1666.	1.0	42
296	Genome-wide association study of endometrial cancer in E2C2. Human Genetics, 2014, 133, 211-224.	3.8	42
297	Relationship of Terminal Duct Lobular Unit Involution of the Breast with Area and Volume Mammographic Densities. Cancer Prevention Research, 2016, 9, 149-158.	1.5	42
298	Patterns and predictors of the breast cancer detection methods in women under 45 years of age (United States). Cancer Causes and Control, 2001, 12, 431-442.	1.8	41
299	Lifetime Number of Ovulatory Cycles and Risks of Ovarian and Endometrial Cancer Among Postmenopausal Women. American Journal of Epidemiology, 2016, 183, 800-814.	3.4	41
300	Relationship of thyroid disease and use of thyroid supplements to breast cancer risk. Journal of Chronic Diseases, 1984, 37, 877-883.	1.2	40
301	Cigarette smoking and breast cancer risk among young women (United States). Cancer Causes and Control, 1998, 9, 583-590.	1.8	40
302	Accelerometer-based measures of active and sedentary behavior in relation to breast cancer risk. Breast Cancer Research and Treatment, 2012, 134, 1279-1290.	2.5	40
303	Anthropometric Measures and Physical Activity and the Risk of Lung Cancer in Never-Smokers: A Prospective Cohort Study. PLoS ONE, 2013, 8, e70672.	2.5	40
304	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
305	Risk factors for endometrial cancer in black and white women: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). Cancer Causes and Control, 2015, 26, 287-296.	1.8	40
306	Sexual, reproductive and contraceptive risk factors for carcinomaâ€inâ€situ of the uterine cervix in Sydney. Medical Journal of Australia, 1989, 150, 125-130.	1.7	39

#	Article	IF	CITATIONS
307	Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers. Breast Cancer Research, 2012, 14, R64.	5.0	39
308	Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the Bâ^1/4FIT Cohort. Hormones and Cancer, 2016, 7, 49-64.	4.9	39
309	Barrier and Spermicidal Contraceptive Methods and Risk of Invasive Cervical Cancer. Epidemiology, 1990, 1, 266-272.	2.7	38
310	Menstrual risk factors and early-onset breast cancer. Cancer Causes and Control, 2000, 11, 451-458.	1.8	38
311	Occupational exposure to organic solvents and breast cancer in women. Occupational and Environmental Medicine, 2010, 67, 722-729.	2.8	38
312	Cancer risk among infertile women with androgen excess or menstrual disorders (including) Tj ETQq0 0 0 rgBT /0	Overlock 1 1.0	.0 Tf 50 542 1
313	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38
314	Invasive Cervical Cancer and Intrauterine Device Use. International Journal of Epidemiology, 1991, 20, 865-870.	1.9	37
315	Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study. BMC Cancer, 2007, 7, 60.	2.6	37
316	Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. Cancer, 2007, 109, 1303-1311.	4.1	37
317	Urinary bisphenol A-glucuronide and postmenopausal breast cancer in Poland. Cancer Causes and Control, 2014, 25, 1587-1593.	1.8	37
318	Long-term Relationship of Ovulation-Stimulating Drugs to Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 584-593.	2.5	37
319	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37
320	Epidemiology of vulvar neoplasia in the NIH-AARP Study. Gynecologic Oncology, 2017, 145, 298-304.	1.4	37
321	Cigarette smoking and endometrial carcinoma risk: the role of effect modification and tumor heterogeneity. Cancer Causes and Control, 2014, 25, 479-489.	1.8	36
322	Sleep duration and breast cancer risk among black and white women. Sleep Medicine, 2016, 20, 25-29.	1.6	36
323	Gestational trophoblastic disease: A case-control study from the People's Republic of China. American Journal of Obstetrics and Gynecology, 1989, 161, 121-127.	1.3	35
324	Injectable contraceptives and risk of invasive cervical cancer: Evidence of an association. International Journal of Cancer, 1990, 46, 5-7.	5.1	35

#	Article	IF	CITATIONS
325	The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Research, 2020, 80, 1210-1218.	0.9	35
326	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	5.1	35
327	Second primary cancers after vulvar and vaginal cancers. American Journal of Obstetrics and Gynecology, 1996, 174, 929-933.	1.3	33
328	Missense Variants in <i>ATM</i> in 26,101 Breast Cancer Cases and 29,842 Controls. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2143-2151.	2.5	33
329	Sex Steroid Hormone Metabolism in Relation to Risk of Aggressive Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2374-2382.	2.5	33
330	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33
331	Associations of fecal microbial profiles with breast cancer and nonmalignant breast disease in the Ghana Breast Health Study. International Journal of Cancer, 2021, 148, 2712-2723.	5.1	33
332	Low Serum and Red Blood Cell Folate Are Moderately, but Nonsignificantly Associated with Increased Risk of Invasive Cervical Cancer in U.S. Women. Journal of Nutrition, 2001, 131, 2040-2048.	2.9	32
333	Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes and Control, 2012, 23, 1839-1852.	1.8	32
334	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 980-987.	2.5	32
335	Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. Breast Cancer Research and Treatment, 2012, 131, 287-294.	2.5	32
336	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. Journal of the National Cancer Institute, 2015, 107, .	6.3	32
337	Circulating antiâ€Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. International Journal of Cancer, 2018, 142, 2215-2226.	5.1	32
338	Comparability of serum, plasma, and urinary estrogen and estrogen metabolite measurements by sex and menopausal status. Cancer Causes and Control, 2019, 30, 75-86.	1.8	32
339	Methylxanthines and breast cancer. International Journal of Cancer, 1987, 40, 469-473.	5.1	31
340	Sinonasal cancer and occupation. Results from the reanalysis of twelve case-control studies. , 1997, 31, 153-165.		31
341	Prospective study of physical activity and the risk of ovarian cancer. Cancer Causes and Control, 2009, 20, 765-773.	1.8	31
342	The relations between cervical cancer and serological markers of nutritional status. Nutrition and Cancer, 1994, 21, 193-201.	2.0	30

#	Article	IF	CITATIONS
343	Fertility Drugs and the Risk of Breast and Gynecologic Cancers. Seminars in Reproductive Medicine, 2012, 30, 131-145.	1.1	30
344	Design considerations for identifying breast cancer risk factors in a populationâ€based study in Africa. International Journal of Cancer, 2017, 140, 2667-2677.	5.1	30
345	Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study. JNCI Cancer Spectrum, 2019, 3, pkz029.	2.9	30
346	Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model. Breast Cancer Research, 2019, 21, 42.	5.0	30
347	Oral Contraceptive Use Among Women in the Military and the General U.S. Population. Journal of Women's Health, 2010, 19, 839-845.	3.3	29
348	Fertility drugs and endometrial cancer risk: results from an extended follow-up of a large infertility cohort. Human Reproduction, 2013, 28, 2813-2821.	0.9	29
349	Prolactin Receptor Expression and Breast Cancer: Relationships with Tumor Characteristics among Pre- and Post-menopausal Women in a Population-Based Case–Control Study from Poland. Hormones and Cancer, 2014, 5, 42-50.	4.9	29
350	Effects of fertility drugs on cancers other than breast and gynecologic malignancies. Fertility and Sterility, 2015, 104, 980-988.	1.0	29
351	Modification of oral contraceptive relationships on breast cancer risk by selected factors among younger women. Contraception, 1997, 55, 197-203.	1.5	28
352	Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer, 2013, 13, 28.	2.6	28
353	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
354	Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. Journal of the National Cancer Institute, 2017, 109, djw251.	6.3	28
355	Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology, 2017, 186, 1329-1340.	3.4	28
356	Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium. International Journal of Cancer, 2019, 145, 58-69.	5.1	28
357	Reproductive factors and risk of breast cancer by tumor subtypes among Ghanaian women: A populationâ€based case–control study. International Journal of Cancer, 2020, 147, 1535-1547.	5.1	28
358	METHYLXANTHINES AND BENIGN BREAST DISEASE1. American Journal of Epidemiology, 1986, 124, 603-611.	3.4	27
359	Human Papillomavirus-Specific Serologic Response in Vulvar Neoplasia. Gynecologic Oncology, 1996, 63, 200-203.	1.4	27
360	Relationships of uterine and ovarian tumors to pre-existing chronic conditions. Gynecologic Oncology, 2007, 107, 487-494.	1.4	27

#	Article	IF	CITATIONS
361	Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study. Gynecologic Oncology, 2011, 120, 167-173.	1.4	27
362	Assay Reproducibility and Interindividual Variation for 15 Serum Estrogens and Estrogen Metabolites Measured by Liquid Chromatography–Tandem Mass Spectrometry. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2649-2657.	2.5	27
363	Association of Active and Sedentary Behaviors with Postmenopausal Estrogen Metabolism. Medicine and Science in Sports and Exercise, 2016, 48, 439-448.	0.4	27
364	Prospective Case-Control Study of Serum Mullerian Inhibiting Substance and Breast Cancer Risk. Journal of the National Cancer Institute, 2009, 101, 1501-1509.	6.3	26
365	Fatherhood and incident prostate cancer in a prospective US cohort. International Journal of Epidemiology, 2011, 40, 480-487.	1.9	26
366	Immunohistochemical analysis of polycyclic aromatic hydrocarbon-DNA adducts in breast tumor tissue. Cancer Letters, 2000, 154, 143-149.	7.2	25
367	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
368	Postmenopausal Hormone-Replacement Therapy — Time for a Reappraisal?. New England Journal of Medicine, 1997, 336, 1821-1822.	27.0	24
369	Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. International Journal of Cancer, 2009, 125, 674-679.	5.1	24
370	No Association between <i>FTO</i> or <i>HHEX</i> and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2106-2109.	2.5	24
371	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
372	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	2.5	24
373	Body mass index, physical activity, and television time in relation to mortality risk among endometrial cancer survivors in the NIH-AARP Diet and Health Study cohort. Cancer Causes and Control, 2016, 27, 1403-1409.	1.8	24
374	Longitudinal Change in Mammographic Density among ER-Positive Breast Cancer Patients Using Tamoxifen. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 212-216.	2.5	24
375	Skin lighteners and hair relaxers as risk factors for breast cancer: results from the Chana breast health study. Carcinogenesis, 2018, 39, 571-579.	2.8	24
376	EDITORIAL COMMENTARY: SMOKING AND CERVICAL CANCER—CURRENT STATUS. American Journal of Epidemiology, 1990, 131, 958-960.	3.4	23
377	Occupation and breast cancer in women 20-44 years of age (United States). Cancer Causes and Control, 2003, 14, 627-637.	1.8	23
378	Genetic variation of Cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women. Pharmacogenetics and Genomics, 2006, 16, 547-553.	1.5	23

#	Article	IF	CITATIONS
379	Oral Contraceptives and Survival in Breast Cancer Patients Aged 20 to 54 Years. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1822-1827.	2.5	23
380	Genetic variation in CYP17 and endometrial cancer risk. Human Genetics, 2008, 123, 155-162.	3.8	23
381	Active and passive cigarette smoking and the risk of endometrial cancer in Poland. European Journal of Cancer, 2010, 46, 690-696.	2.8	23
382	Circulating Sex Hormones and Terminal Duct Lobular Unit Involution of the Normal Breast. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2765-2773.	2.5	23
383	Comparison of Mammographic Density Assessed as Volumes and Areas among Women Undergoing Diagnostic Image-Guided Breast Biopsy. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2338-2348.	2.5	23
384	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	3.8	23
385	Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial. Gynecologic Oncology, 2015, 139, 70-76.	1.4	23
386	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
387	Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women. JAMA Network Open, 2020, 3, e203645.	5.9	23
388	MENARCHEAL AGE AND MISCARRIAGE1. American Journal of Epidemiology, 1983, 117, 634-636.	3.4	22
389	Relative and Attributable Risk for Cervical Cancer: A Comparative Study in the United States and Italy. International Journal of Epidemiology, 1990, 19, 539-545.	1.9	22
390	Measurement of Sex Steroid Hormones in Breast Adipocytes: Methods and Implications. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1891-1895.	2.5	22
391	Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. International Journal of Cancer, 2009, 124, 1716-1720.	5.1	22
392	Increased risk for cancer among offspring of women with fertility problems. International Journal of Cancer, 2013, 133, 1180-1186.	5.1	22
393	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
394	Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications. Journal of Clinical Oncology, 2016, 34, 2093-2097.	1.6	22
395	Fertility problems and breast cancer risk in young women: a case-control study in the United States. Cancer Causes and Control, 1998, 9, 331-339.	1.8	21
396	A Debriefing Session with a Nutritionist Can Improve Dietary Assessment Using Food Diaries. Journal of Nutrition, 2006, 136, 440-445.	2.9	21

#	Article	lF	CITATIONS
397	Comprehensive Assessment of Genetic Variation of Catechol-O-Methyltransferase and Breast Cancer Risk. Cancer Research, 2006, 66, 9781-9785.	0.9	21
398	Common Genetic Variation in GATA-Binding Protein 3 and Differential Susceptibility to Breast Cancer by Estrogen Receptor  Tumor Status. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2269-2275.	2.5	21
399	Risks of cancer among a cohort of 23,935 men and women with osteoporosis. International Journal of Cancer, 2008, 122, 1879-1884.	5.1	21
400	Nonsteroidal Anti-Inflammatory Drug Use and Endometrial Cancer Risk in the NIH-AARP Diet and Health Study. Cancer Prevention Research, 2009, 2, 466-472.	1.5	21
401	Timing of births and endometrial cancer risk in Swedish women. Cancer Causes and Control, 2009, 20, 1441-1449.	1.8	21
402	Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer. Breast Cancer Research and Treatment, 2013, 137, 837-847.	2.5	21
403	Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	3.4	21
404	Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. Breast Cancer Research, 2017, 19, 28.	5.0	21
405	Diet and the risk of vulvar cancer. Annals of Epidemiology, 1991, 1, 427-437.	1.9	20
406	Do alcohol intake and mammographic densities interact in regard to the risk of breast cancer?. Cancer, 1993, 71, 3029-3035.	4.1	20
407	HORMONE REPLACEMENT THERAPY AND RISK FOR BREAST CANCER. Endocrinology and Metabolism Clinics of North America, 1997, 26, 361-378.	3.2	20
408	Molar pregnancy and risk for cancer in women and their male partners. American Journal of Obstetrics and Gynecology, 1999, 181, 630-634.	1.3	20
409	Intake of fruits, and vegetables in relation to breast cancer risk by hormone receptor status. Breast Cancer Research and Treatment, 2007, 107, 113-117.	2.5	20
410	Assay reproducibility and within-person variation of Müllerian inhibiting substance. Fertility and Sterility, 2010, 94, 301-304.	1.0	20
411	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	2.5	20
412	Racial differences in the risk of invasive squamous-cell cervical cancer. Cancer Causes and Control, 1991, 2, 283-290.	1.8	19
413	Hormones and endometrial cancer—new data from the Million Women Study. Lancet, The, 2005, 365, 1517-1518.	13.7	19
414	Estrogen Metabolism and Mammographic Density in Postmenopausal Women: A Cross-Sectional Study. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1582-1591.	2.5	19

#	Article	IF	CITATIONS
415	Breast cancer risk in older women: results from the NIH-AARP Diet and Health Study. Cancer Causes and Control, 2014, 25, 843-857.	1.8	19
416	Cell-Cycle Protein Expression in a Population-Based Study of Ovarian and Endometrial Cancers. Frontiers in Oncology, 2015, 5, 25.	2.8	19
417	Tobacco and Alcohol in Relation to Male Breast Cancer: An Analysis of the Male Breast Cancer Pooling Project Consortium. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 520-531.	2.5	19
418	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19
419	GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer. Human Molecular Genetics, 2016, 25, ddw092.	2.9	19
420	Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health Study. American Journal of Epidemiology, 2018, 187, 1630-1641.	3.4	19
421	Weight, Height, and Body Mass Index and Risk for Ovarian Cancer in a Cohort Study. Annals of Epidemiology, 2006, 16, 869-876.	1.9	18
422	Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland. Breast Cancer Research, 2011, 13, R42.	5.0	18
423	Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies. Cancer Prevention Research, 2012, 5, 435-443.	1.5	18
424	Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. Carcinogenesis, 2014, 35, 2068-2073.	2.8	18
425	Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1419-1422.	2.5	18
426	Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Research, 2016, 18, 24.	5.0	18
427	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
428	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	3.8	18
429	Occupation and breast cancer risk in Polish women: A population-based case-control study. American Journal of Industrial Medicine, 2007, 50, 97-111.	2.1	17
430	Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH–AARP Diet and Health Study Cohort. Cancer Causes and Control, 2012, 23, 487-496.	1.8	17
431	Risk Factors for Specific Histopathological Types of Postmenopausal Breast Cancer in the NIH-AARP Diet and Health Study. American Journal of Epidemiology, 2013, 178, 359-371.	3.4	17
432	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	2.9	17

#	Article	IF	CITATIONS
433	Occupation and Cervical Cancer. Journal of Occupational and Environmental Medicine, 1995, 37, 357-361.	1.7	16
434	Tubal Sterilization and Risk of Cancer of the Endometrium. Gynecologic Oncology, 2000, 79, 482-484.	1.4	16
435	Intrauterine environment and breast cancer risk in a population-based case-control study in Poland. International Journal of Cancer, 2006, 119, 2136-2141.	5.1	16
436	Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Research and Treatment, 2014, 143, 181-187.	2.5	16
437	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
438	Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease. Cancer Causes and Control, 2020, 31, 309-320.	1.8	16
439	Plasma Carotenoid- and Retinol-Weighted Multi-SNP Scores and Risk of Breast Cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 927-936.	2.5	15
440	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
441	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
442	Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. International Journal of Cancer, 2019, 145, 2051-2060.	5.1	15
443	The association between oral contraceptive use and lobular and ductal breast cancer in young women. International Journal of Cancer, 2008, 122, 936-941.	5.1	14
444	Alcohol and endometrial cancer risk in the NIHâ€AARP diet and health study. International Journal of Cancer, 2011, 128, 2953-2961.	5.1	14
445	Endometrial thickness and risk of breast and endometrial carcinomas in the prostate, lung, colorectal and ovarian cancer screening trial. International Journal of Cancer, 2014, 134, 954-960.	5.1	14
446	Reproducibility of an assay to measure serum progesterone metabolites that may be related to breast cancer risk using liquid chromatography-tandem mass spectrometry. Hormone Molecular Biology and Clinical Investigation, 2015, 23, 79-84.	0.7	14
447	Sitting, physical activity, and serum oestrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. British Journal of Cancer, 2017, 117, 1070-1078.	6.4	14
448	Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study. British Journal of Cancer, 2018, 118, 448-457.	6.4	14
449	Recruiting population controls for case-control studies in sub-Saharan Africa: The Ghana Breast Health Study. PLoS ONE, 2019, 14, e0215347.	2.5	14
450	Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. International Journal of Cancer, 2021, 148, 2068-2078.	5.1	14

#	Article	IF	CITATIONS
451	Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 607-12.	2.5	14
452	Relationship of Benign Breast Disease to Breast Cancer. Annals of the New York Academy of Sciences, 1990, 586, 266-271.	3.8	13
453	Menopause and the Risk of Breast Cancer. Annals of the New York Academy of Sciences, 1990, 592, 357-362.	3.8	13
454	Genetic Variation in the Androgen Receptor Gene and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 585-589.	2.5	13
455	Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	2.5	13
456	Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy. Hormones and Cancer, 2016, 7, 305-315.	4.9	13
457	Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study. Cancer Causes and Control, 2019, 30, 1201-1211.	1.8	13
458	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
459	The oral microbiome and breast cancer and nonâ€malignant breast disease, and its relationship with the fecal microbiome in the Chana Breast Health Study. International Journal of Cancer, 0, , .	5.1	13
460	Serum selenium and the risk of cervical cancer among women in the United States. Cancer Causes and Control, 2002, 13, 517-526.	1.8	12
461	Exome-Wide Association Study of Endometrial Cancer in a Multiethnic Population. PLoS ONE, 2014, 9, e97045.	2.5	12
462	Receipt of adjuvant endometrial cancer treatment according to race: anÂNRG Oncology/Gynecologic Oncology Group 210 Study. American Journal of Obstetrics and Gynecology, 2018, 219, 459.e1-459.e11.	1.3	12
463	Application of convolutional neural networks to breast biopsies to delineate tissue correlates of mammographic breast density. Npj Breast Cancer, 2019, 5, 43.	5.2	12
464	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
465	Hormones and risk of cancers of the breast and ovary. Cancer Causes and Control, 1996, 7, 569-571.	1.8	11
466	Summary of the workshop. , 1998, 83, 595-599.		11
467	Characteristics Associated with Recent Recreational Exercise Among Women 20 to 44 Years of Age. Women and Health, 2001, 31, 81-96.	1.0	11
468	<i>HSD17B1</i> Genetic Variants and Hormone Receptor–Defined Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2766-2772.	2.5	11

#	Article	IF	CITATIONS
469	Relationships between mammographic density, tissue microvessel density, and breast biopsy diagnosis. Breast Cancer Research, 2016, 18, 88.	5.0	11
470	Pre-diagnosis body mass index, physical activity and ovarian cancer mortality. Gynecologic Oncology, 2019, 155, 105-111.	1.4	11
471	Breast Cancer Risk Among Women Under 55 Years of Age by Joint Effects of Usage of Oral Contraceptives and Hormone Replacement Therapy. Menopause, 1998, 3, 145???151.	2.0	10
472	Defining IVF terminology. Reproductive BioMedicine Online, 2007, 14, 553-554.	2.4	10
473	Relationship of Serum Estrogens and Metabolites with Area and Volume Mammographic Densities. Hormones and Cancer, 2015, 6, 107-119.	4.9	10
474	Assessment of Multifactor Gene–Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	2.5	10
475	Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause, 2018, 25, 1195-1200.	2.0	10
476	Relationship of circulating insulin-like growth factor-I and binding proteins 1–7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. Breast Cancer Research, 2019, 21, 81.	5.0	10
477	Cancer Mortality Among Patients With Hansen's Disease. Journal of the National Cancer Institute, 1984, 72, 109-114.	6.3	9
478	RE. "TWIN MEMBERSHIP AND BREAST CANCER RISK― American Journal of Epidemiology, 1994, 140, 575-57	6.3.4	9
479	Serum Antibodies to HPV 16 Virus-Like Particles Are Not Associated with Penile Cancer in Chinese Males. Viral Immunology, 1996, 9, 23-25.	1.3	9
480	Cancer risk in menopausal women. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 293-307.	2.8	9
481	Menopausal hormone therapy and mortality among endometrial cancer patients in the NIH-AARP Diet and Health Study. Cancer Causes and Control, 2015, 26, 1055-1063.	1.8	9
482	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	2.5	9
483	Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast. International Journal of Cancer, 2017, 140, 825-832.	5.1	9
484	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
485	Involution of Breast Lobules, Mammographic Breast Density and Prognosis Among Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Patients. Journal of Clinical Medicine, 2019, 8, 1868.	2.4	9
486	Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 636-642.	2.5	9

#	Article	IF	CITATIONS
487	Ovarian volumes among women with endometrial carcinoma: Associations with risk factors and serum hormones. Gynecologic Oncology, 2007, 107, 431-435.	1.4	8
488	Post-diagnosis body mass index and mortality among women diagnosed with endometrial cancer: Results from the Women's Health Initiative. PLoS ONE, 2017, 12, e0171250.	2.5	8
489	Serum insulinâ€like growth factor (IGF)â€l and IGF binding proteinâ€3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank. International Journal of Cancer, 2018, 143, 496-507.	5.1	8
490	Do metabolites account for higher serum steroid hormone levels measured by RIA compared to mass spectrometry?. Clinica Chimica Acta, 2018, 484, 223-225.	1.1	8
491	Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?. International Journal of Cancer, 2019, 144, 730-740.	5.1	8
492	Cognitive achievements in school-age children born following assisted reproductive technology treatments: A prospective study. Early Human Development, 2021, 155, 105327.	1.8	8
493	Interactions between benign breast disease and other risk factors for breast cancer. Journal of Chronic Diseases, 1983, 36, 525-531.	1.2	7
494	Association of Serum Sex Steroid Hormone Hemodilution and Body Mass Index Among Healthy Postmenopausal Women. Annals of Epidemiology, 2011, 21, 466-471.	1.9	7
495	A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget, 2016, 7, 7381-7389.	1.8	7
496	Mammographic parenchymal history of breast cancer patterns and family. Cancer, 1992, 69, 602-603.	4.1	6
497	RE: "SHOULD WE CONSIDER A SUBJECT'S KNOWLEDGE OF THE ETIOLOGIC HYPOTHESIS IN THE ANALYSIS OF CASE-CONTROL STUDIES?â€, American Journal of Epidemiology, 1994, 140, 1054-1056.	3.4	6
498	Exposure to Breastmilk and Risk of Breast Cancer. Epidemiology, 1995, 6, 198.	2.7	6
499	Clarifying breast cancer risks associated with menopausal hormone therapy. Lancet Oncology, The, 2006, 7, 885-886.	10.7	6
500	Relationship of Serum Progesterone and Progesterone Metabolites with Mammographic Breast Density and Terminal Ductal Lobular Unit Involution among Women Undergoing Diagnostic Breast Biopsy. Journal of Clinical Medicine, 2020, 9, 245.	2.4	6
501	Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 719-726.	2.5	6
502	Long-Term Fracture Risk among Infertile Women: A Population-Based Cohort Study. Journal of Women's Health and Gender-Based Medicine, 2001, 10, 289-297.	1.5	5
503	Lobular Involution, Mammographic Density, and Breast Cancer Risk: Visualizing the Future?. Journal of the National Cancer Institute, 2010, 102, 1685-1687.	6.3	5
504	Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. Carcinogenesis, 2011, 32, 1862-1866.	2.8	5

#	Article	IF	CITATIONS
505	Fine mapping of 14q24.1 breast cancer susceptibility locus. Human Genetics, 2012, 131, 479-490.	3.8	5
506	Menopausal hormone therapy and mortality among women diagnosed with ovarian cancer in the NIH-AARP Diet and Health Study. Gynecologic Oncology Reports, 2015, 13, 13-17.	0.6	5
507	Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissue. Breast Cancer Research and Treatment, 2016, 158, 341-350.	2.5	5
508	Anti-Mullerian hormone and endometrial cancer: a multi-cohort study. British Journal of Cancer, 2017, 117, 1412-1418.	6.4	5
509	Fertility Status and Cancer. Seminars in Reproductive Medicine, 2017, 35, 291-297.	1.1	5
510	Antiâ€Müllerian hormone and risk of ovarian cancer in nine cohorts. International Journal of Cancer, 2018, 142, 262-270.	5.1	5
511	Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast. Npj Breast Cancer, 2020, 6, 41.	5.2	5
512	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
513	Breast Cancer Risk After Use of Fertility Drugs: Stimulating New Controversy. Journal of the National Cancer Institute, 2012, 104, 962-964.	6.3	4
514	Discovery of structural deletions in breast cancer predisposition genes using whole genome sequencing data from > 2000 women of African-ancestry. Human Genetics, 2021, 140, 1449-1457.	3.8	4
515	Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. Npj Precision Oncology, 2021, 5, 83.	5.4	4
516	Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana Breast Health Study. Breast Cancer Research, 2022, 24, 9.	5.0	4
517	Epidemiology of Uterine Corpus Cancers. , 2004, , 188-207.		3
518	Re: More data regarding the effects of passive smoking on breast cancer risk among younger women. International Journal of Cancer, 2007, 120, 2517-2518.	5.1	3
519	Unraveling Genes, Hormones, and Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 641-642.	6.3	3
520	The Effect of Estrogen Plus Progestin Hormone Therapy on Breast Cancer Mortality: Still Unresolved. Journal of the National Cancer Institute, 2013, 105, 513-514.	6.3	3
521	Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy. BMC Cancer, 2015, 15, 823.	2.6	3
522	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3

#	Article	IF	CITATIONS
523	Endogenous Progestogens and Colorectal Cancer Risk among Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1100-1105.	2.5	3
524	Epidemiology of Breast Cancer. , 2011, , 25-55.		3
525	Relation of circulating estrogens with hair relaxer and skin lightener use among postmenopausal women in Ghana. Journal of Exposure Science and Environmental Epidemiology, 2023, 33, 301-310.	3.9	3
526	Breast Cancer Risk in Women from Ghana Carrying Rare Germline Pathogenic Mutations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1593-1601.	2.5	3
527	Do breast implants after a mastectomy affect subsequent prognosis and survival?. Breast Cancer Research, 2005, 7, 61-3.	5.0	2
528	Hormones and Breast Cancer: What's the Story?. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1697-1699.	2.5	2
529	Physical Activity and Risk of Male Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1898-1901.	2.5	2
530	When the Ideal Meets the Feasible: Constructing a Protocol for Developmental Assessment at Early School-Age. Frontiers in Pediatrics, 2018, 6, 256.	1.9	2
531	How Are They Doing? Neurodevelopmental Outcomes at School Age of Children Born Following Assisted Reproductive Treatments. Journal of Child Neurology, 2021, 36, 262-271.	1.4	2
532	Breast Cancer Risk Factors and Circulating Anti-Müllerian Hormone Concentration in Healthy Premenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4542-e4553.	3.6	2
533	Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The B <b>â^1/4</b> FIT Cohort. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2030-2037.	2.5	2
534	Mammographic densities and risk of breast cancer. , 1991, 67, 2833.		2
535	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. The Clinical Journal of Pathology, 2014, , n/a-n/a.	0.0	2
536	THE FIRST AUTHOR REPLIES. American Journal of Epidemiology, 1982, 115, 796-797.	3.4	1
537	INTRODUCTION TO CANCER. , 2000, , 855-862.		1
538	Epidemiologic issues related to the association between physical activity and breast cancer. , 1998, 83, 600.		1
539	Abstract 4168: Alcohol consumption and risk of breast cancer in postmenopausal women: the NIH-AARP Diet and Health Study. , 2008, , .		1
540	Abstract 2519: Is accelerometer-measured physical activity associated with urinary estrogens and estrogen metabolites among postmenopausal women? , 2013, , .		1

#	Article	IF	CITATIONS
541	Risk Factors for Cervical Cancer: Comments on Attributable Risk Calculations and the Evaluation of Screening in Case-Control Studies. International Journal of Epidemiology, 1991, 20, 1142-1143.	1.9	0
542	Hormones and Breast and Endometrial Cancers: Preventive Strategies and Future Research. Environmental Health Perspectives, 1995, 103, 185.	6.0	0
543	NIH follow-up study of women with augmentation mammoplasty: Investigator replies. Lancet, The, 1998, 351, 1814.	13.7	Ο
544	Cancer prevention in postmenopausal women. The Journal of the British Menopause Society, 2001, 7, 151-160.	1.3	0
545	Reply: Do drugs that stimulate ovulation increase the risk for endometrial stromal sarcoma?. Human Reproduction, 2005, 20, 1112-1113.	0.9	0
546	Response. Journal of the National Cancer Institute, 2014, 106, djt377-djt377.	6.3	0
547	Health and Humanity: A History of the Johns Hopkins Bloomberg School of Public Health, 1935–1985. American Journal of Epidemiology, 2016, 184, 787-788.	3.4	0
548	Fatherhood status in relation to prostate cancer risks in two large U.S.â€based prospective cohort studies. Cancer Medicine, 2021, 10, 405-415.	2.8	0
549	Menopause Hormone Replacement Therapy and Cancer: Epidemiology. Medical Science Symposia Series, 2002, , 329-338.	0.0	0
550	Environmental Factors Related to Cancers in Postmenopausal Women. Medical Science Symposia Series, 2002, , 181-188.	0.0	0
551	Prevention of Gynecologic Malignancies. , 2004, , 883-919.		0
552	Abstract 2779: Relationship of mammographic density with breast cancer subtypes. , 2010, , .		0
553	Abstract 2786: Methylation profiling of endometrial cancers from a population-based case control study. , 2010, , .		0
554	Abstract 3477: Discovery and validation of methylation markers for early detection of endometrial cancer , 2013, , .		0
555	Abstract 2285: Risk factors for endometrial cancer in black and white women: A pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2) , 2013, , .		0
556	Abstract 152: Endometrial thickness and risk of sex hormone-related cancers in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial , 2013, , .		0
557	Abstract 154: Lifetime ovulatory cycles and risk of ovarian and endometrial cancers , 2013, , .		0
558	Abstract 2167: Infertility and risk of incident endometrial carcinoma: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium. , 2014, , .		0

#	Article	IF	CITATIONS
559	Abstract 1603: Estrogen metabolites and colorectal cancer risk in postmenopausal women in the Breast and Bone Follow-up to the Fracture Intervention Trial (Bâ^¼FIT). , 2014, , .		0
560	Abstract 874: Autoantibody biomarker discovery in basal-like breast cancer using nucleic acid programmable protein array. , 2014, , .		0
561	Role of Estrogen and Progesterone in Obesity Associated Gynecologic Cancers. Energy Balance and Cancer, 2018, , 41-61.	0.2	0